**Potential Value of Cyclurad™ Ingredient Identified for Treating Depression**

The active ingredient of Cyclurad™ by NeuroRx, Inc., has been identified as potentially promising in the treatment of depression, according to a report in the *American Journal of Psychiatry*.

The American Psychiatric Association Task Force identified D-cycloserine as one of only two molecules currently on the research horizon that shows promise for repeated administration in the treatment of depression via modulation of the NMDA receptor. D-cycloserine is one of the two active ingredients of Cyclurad.

The task force conducted an extensive review of the scientific literature. The report highlights the short-term nature of the ketamine response and the documented incidence of hallucinations and other psychomimetic side effects as limiting the use of ketamine in isolation for the treatment of depression. The findings continued with a comprehensive analysis of all currently investigational molecules that act on the NMDA receptor and may be valuable in the treatment of depression.

**GeneSight® Improved to Include More Options for Making Neuropsychiatric Disorder Medication Decisions**

Assurex Health, Inc., announced a significant enhancement to its GeneSight® Psychotropic test, giving health care providers an expanded range of options to help make medication decisions for patients with depression, anxiety, bipolar disorder, posttraumatic stress disorder, schizophrenia, and other behavioral health conditions.

With the addition of two new drug classes, 17 U.S. Food and Drug Administration–approved medications, and four clinically validated genes, GeneSight Psychotropic now covers 97% of prescriptions written to treat depression, anxiety, bipolar disorder, and schizophrenia.

GeneSight Psychotropic is a comprehensive neuropsychiatric pharmacogenomics test that (a) uses combinatorial pharmacogenomics; (b) has the most clinical data supporting its clinical validity and use; (c) includes more relevant genes than its competition; and (d) analyzes the most relevant medications and drug classes that cover neuropsychiatric disorders.

The report is the second independent, peer-reviewed confirmation of the potential value of D-cycloserine in extending the effect of ketamine in the treatment of acute depression.
